Buy Evermil : Everolimus 5 Mg Tablets Online

Description

Overview: Evermil is a medication manufactured by Glenmark (Onkos) Pharmaceuticals Ltd. containing the active substance Everolimus. It belongs to a class of medications known as mammalian target of rapamycin (mTOR) inhibitors. Evermil is primarily used in the treatment of various types of cancer, including breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumors, gastrointestinal stromal tumors, and advanced hormone receptor-positive, HER2-negative breast cancer.

Active Substance:

• Everolimus: Evermil contains Everolimus, which is a derivative of rapamycin and an inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway. mTOR is a protein kinase that regulates cellular processes such as cell growth, proliferation, angiogenesis, and metabolism. By inhibiting mTOR, Everolimus blocks the downstream signaling pathways involved in tumor cell proliferation and angiogenesis, thereby inhibiting tumor growth and progression.

Indications: Evermil (Everolimus) 5 mg Tablets are indicated for:

1. Breast Cancer: It is used in combination with exemestane for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women who have progressed on prior endocrine therapy.
2. Renal Cell Carcinoma: Evermil is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
3. Pancreatic Neuroendocrine Tumors: It is used for the treatment of advanced pancreatic neuroendocrine tumors (pNET) that are unresectable, locally advanced, or metastatic.
4. Gastrointestinal Stromal Tumors: Evermil is indicated for the treatment of advanced gastrointestinal stromal tumors (GIST) that are resistant or intolerant to imatinib and sunitinib.

Mechanism of Action: Everolimus exerts its therapeutic effects by inhibiting the activity of the mammalian target of rapamycin (mTOR) signaling pathway. mTOR is a central regulator of cell growth, proliferation, and survival, and its dysregulation is implicated in the pathogenesis of cancer. By inhibiting mTOR, Everolimus blocks the downstream signaling pathways that promote tumor cell growth, proliferation, angiogenesis, and survival, leading to inhibition of tumor growth and progression.

Dosage and Administration: The dosage of Evermil (Everolimus) 5 mg Tablets is determined by the prescribing healthcare provider based on factors such as the type of cancer being treated, the patient’s body weight, and renal function. It is usually administered orally once daily, with or without food, at the same time each day. The tablets should be swallowed whole with a glass of water and should not be crushed, chewed, or split.

Potential Side Effects: Common side effects associated with Evermil may include:

• Fatigue or weakness
• Stomatitis (mouth sores)
• Rash or skin reactions
• Diarrhea
• Nausea or vomiting
• Decreased appetite
• Infections
• Anemia

Precautions:

• Evermil should be used with caution in patients with hepatic impairment, renal impairment, or immunosuppression.
• It is contraindicated in pregnant women due to the potential risk of fetal harm.
• Patients should be monitored regularly for blood counts, renal function, and signs of infection during treatment with Evermil.
• Evermil may interact with other medications, including strong CYP3A4 inducers or inhibitors, immunosuppressants, and antifungal agents, necessitating dosage adjustments or close monitoring.

In conclusion, Evermil (Everolimus) 5 mg Tablets manufactured by Glenmark (Onkos) Pharmaceuticals Ltd. are indicated for the treatment of various types of cancer, including breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumors, and gastrointestinal stromal tumors. By inhibiting the mTOR signaling pathway, Evermil inhibits tumor growth and progression. While generally well-tolerated, Evermil may cause side effects and should be used cautiously under medical supervision.